RLYB · Rallybio Corporation

The thesis

Rallybio's shares now price a merger that is days from a vote: an estimated $13.56 per share cash distribution, one contingent value right per share, and about 2.8% of the combined Avenzo Therapeutics. The stockholder vote on 4 November 2026 and the expected close on 6 November 2026 settle the case. The close was $15.99 on 28 October 2026, 7.1% under the 52-week high of $17.22 (adjusted daily closes).

The narrative is maturing: the deal was announced on 1 June 2026, and the procedural steps have now resolved. The proxy statement/prospectus was filed on 15 October 2026, and Rallybio's 8-K of 26 October 2026 declared the distribution. What remains is a small stake in an early-stage oncology company.

Rallybio's 8-K estimates the distribution at $82.7 million in total, about $13.56 per share, based on 6,378,168 shares and share equivalents at 21 October 2026. The filing says the final amount may be higher or lower and that payment depends on the required stockholder vote.

Bullish and bearish views on Rallybio Corporation

The bull case on Rallybio Corporation (RLYB), in brief: Meeting date is now fixed. The bear case: The residual stake is small.

Bull case

• Meeting date is now fixed. The Rallybio proxy statement/prospectus dated 15 October 2026 (Form 424B3) sets the online annual meeting for 4 November 2026. The record date for voting is 11 September 2026. This removes the main procedural doubt in the previous note.
• Cash return is declared. The 26 October 2026 8-K declares an estimated $82.7 million distribution, about $13.56 per share, with funds deposited with the transfer agent on 5 November 2026 and a payment date of 13 November 2026. The estimate reflects the amount by which Net Cash, as the merger agreement defines it, exceeds zero.
• Contingent value right is set up. The same 8-K fixes the close of business on 5 November 2026 as the record date for the contingent value right. It pays only if legacy-asset and Recursion proceeds clear a $1 million minimum, through 31 December 2031.
• Financing sits alongside the merger. The 1 June 2026 announcement described an oversubscribed $215 million private placement. Rallybio said it funds operations into late 2028.

Bear case

• The residual stake is small. Rallybio holders are expected to own about 2.8% of the combined company on a fully diluted basis, per the 15 October 2026 prospectus. That estimate rests on a $15.0 million Rallybio valuation against a fixed $300.0 million Avenzo valuation. The 0.5020 exchange ratio adjusts to final Net Cash and share count at closing.
• Reported quarterly loss missed. Benzinga reported on 27 October 2026 that Rallybio's third-quarter loss was $(0.48) per share, against an estimate of $(0.21). Net Cash was about $82.2 million at 15 August 2026, down from about $92.9 million at 30 June 2026.
• Vote or conditions could fail. The 8-K ties payment to the required stockholder vote and says the close is expected on or about 6 November 2026 only if conditions are met. A failed vote or a delayed close would leave the distribution unpaid.
• The 6 November 2026 ex-date resets the unadjusted quote by roughly the size of the distribution, which widens price moves in a stock with that little volume.

Price setup

The last close of $15.99 on 28 October 2026 is 7.1% under the 52-week high of $17.22. It follows a $16.77 close on 15 October 2026. The shares rose 0.4% over three months, and the 14-day relative strength index is 30.8, a level often read as oversold.

The 8-K says the ex-dividend date is expected on 6 November 2026, the day of the expected closing, because the distribution exceeds 25% of the share price at declaration. A due bill period runs from 4 November 2026 through 6 November 2026, during which buyers receive the distribution and sellers give it up. Price levels in this note follow the split- and distribution-adjusted series, which restates earlier closes once the ex-date passes.

Crowding evidence is limited. No SEC Form 4 insider sales or share issuance appear in company news. Attention is event-driven, with the vote and ex-date inside the next ten sessions. Rallybio's 1-for-8 reverse split took effect on 6 February 2026.

Catalysts, next 30 days

• 6 November 2026: Expected merger closing and ex-dividend date; the combined company is expected to be renamed Avenzo Therapeutics and trade as AVZO.
• 13 November 2026: Distribution payment date. The final per-share amount may differ from the $13.56 estimate.

Elapsed catalysts

• 4 November 2026: Rallybio annual meeting (online) and start of the due bill period. The stockholder vote decides whether the distribution and merger proceed. (passed 2d ago)
• 5 November 2026: Record date for the cash distribution and the contingent value right; funds go to the transfer agent. (passed 1d ago)

What would change the view

A failed stockholder vote on 4 November 2026, a terminated merger agreement, or no completed merger by 31 December 2026 would break the case. A final distribution well below the $13.56 estimate would also weaken it. The price condition is a weekly close below $14, which sits just above the estimated distribution; the graded series restates on the ex-date.

After the close, the case rests on Avenzo's clinical program. Avenzo announced on 10 September 2026 that preliminary AVZO-1418 results would be presented at the EORTC-NCI-AACR symposium. The rating is lower than the previous note's because the dated deal catalyst is now resolved within days and the remaining return depends on a 2.8% stake in an early-stage company.

What it trades with

Before closing, the shares track the merger and the cash distribution rather than the oncology sector or small-cap biotech indexes. After the 6 November 2026 expected close, the stock becomes AVZO and is expected to trade with clinical-stage oncology shares. Recursion's REV102 proceeds feed the contingent value right, but they do not move the shares today.